Intellia Therapeutics, Inc. (NTLA) News
Filter NTLA News Items
NTLA News Results
|Loading, please wait...|
NTLA News Highlights
- For NTLA, its 30 day story count is now at 14.
- Over the past 23 days, the trend for NTLA's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- The most mentioned tickers in articles about NTLA are VIVO, CAS and EDIT.
Latest NTLA News From Around the Web
Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate. NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms' Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML). Intellia plans to initiate patient screening by the end of 2021 for
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing com
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
CRISPR-CAS 9 Technology Market Revolutionary CAGR +20% by 2028 with AstraZeneca, CRISPR Therapeutics, Editas Medicine, eGenesis, F. Hoffmann-La Roche, GenScript, Danaher, Intellia Therapeutics, Lonza, Merck KGaA, Intellia Therapeutics, Takara Bio, Thermo
CRISPR-CAS 9 Technology Market is projected to thrive $5 Bn at a CAGR +20% by the end of 2028. CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering
Intellia Therapeutics Inc. NTLA: Daily Elliott Wave Chart. The triangle is moving nicely as predicted last week. Id like to see one last leg down
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following virtual healthcare investor conferences in September:
In this article, we discuss the 12 best ARK stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best ARK Stocks to Invest In. As technology and growth stocks surged during the pandemic, ARK Investment Management and Cathie Wood became two of retail investors’ favorites over the previous […]
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.